O - Simulations Plus: Has Fantastic Total Return And Growth In The Drug Simulation Testing Market
This article is about Simulations Plus (SLP) and why it's a choice for the speculative growth investor looking for the latest technology in drug development. Simulations Plus is a provider of simulation and modeling software for pharmaceutical product development in the United States and foreign countries. What interested me in this company was its product but most of all the high insider ownership of 31%.
Simulations Plus is being reviewed using The Good Business Portfolio guidelines, but some of my guidelines are not germane for a small-cap company like SLP. The company has